223 related articles for article (PubMed ID: 12109803)
1. Irinotecan in epithelial ovarian cancer.
Gershenson DM
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):29-31. PubMed ID: 12109803
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
Bodurka DC; Levenback C; Wolf JK; Gano J; Wharton JT; Kavanagh JJ; Gershenson DM
J Clin Oncol; 2003 Jan; 21(2):291-7. PubMed ID: 12525521
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan for the treatment of cervical cancer.
Verschraegen CF
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):32-4. PubMed ID: 12109804
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
5. In vitro sensitivity of fresh ovarian carcinoma specimens to CPT-11 (irinotecan).
O'meara AT; Sevin BU
Gynecol Oncol; 1999 Feb; 72(2):143-7. PubMed ID: 10021292
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan in cervical cancer.
Kavanagh JJ; Verschraegen CF; Kudelka AP
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):94-8. PubMed ID: 9726099
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of irinotecan in patients with colorectal cancer.
Rothenberg ML
Semin Oncol; 1998 Oct; 25(5 Suppl 11):39-46. PubMed ID: 9786315
[TBL] [Abstract][Full Text] [Related]
8. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
9. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
Rougier P; Bugat R
Semin Oncol; 1996 Feb; 23(1 Suppl 3):34-41. PubMed ID: 8633252
[TBL] [Abstract][Full Text] [Related]
10. Role of topoisomerase I inhibitors in small-cell lung cancer.
Fukuoka M
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):9-13. PubMed ID: 11497234
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan therapy for small-cell lung cancer.
Sandler A
Oncology (Williston Park); 2002 Apr; 16(4):419-25, 428, 433; discussion 433-4, 437-8. PubMed ID: 12017533
[TBL] [Abstract][Full Text] [Related]
12. Clinical trials with the topoisomerase I inhibitors.
Burris HA; Rothenberg ML; Kuhn JG; Von Hoff DD
Semin Oncol; 1992 Dec; 19(6):663-9. PubMed ID: 1334279
[TBL] [Abstract][Full Text] [Related]
13. Japanese ovarian trials: focus on irinotecan.
Sugiyama T; Yakushiji M; Ochiai K; Noda K
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):29-33. PubMed ID: 12800603
[TBL] [Abstract][Full Text] [Related]
14. CPT-11: an original spectrum of clinical activity.
Rothenberg ML
Semin Oncol; 1996 Feb; 23(1 Suppl 3):21-6. PubMed ID: 8633249
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma.
Sarris AH; Romaguera J; Hagemeister FB; Rodriguez MA; McLaughlin P; Pro B; Younes A; Mesina O; Cabanillas F; Medeiros LJ; Samuels B
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):53-6. PubMed ID: 11497233
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
Saijo N; Horiike A
Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):11-6. PubMed ID: 15255163
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase I inhibitors in the treatment of colorectal cancer.
Rothenberg ML; Blanke CD
Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
[TBL] [Abstract][Full Text] [Related]
19. [Irinotecan hydrochloride (CPT-11) for advanced cervical cancer].
Terauchi F
Nihon Rinsho; 2004 Oct; 62 Suppl 10():175-8. PubMed ID: 15535228
[No Abstract] [Full Text] [Related]
20. [CPT-11 (irinotecan)--evidence from molecular and pharmacological studies and clinical applications].
Isobe T; Ishikawa N; Oguri T
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1267-78. PubMed ID: 10945026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]